e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
IPF: from bench to bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc)
Jörg Distler (Erlangen, Germany), Jingang Huang, Christian Beyer, Katrin Palumbo-Zerr, Yun Zhang, Stefan-Lutz Wollin, Jörg Distler
Source:
International Congress 2015 – IPF: from bench to bedside
Session:
IPF: from bench to bedside
Session type:
Poster Discussion
Number:
3038
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jörg Distler (Erlangen, Germany), Jingang Huang, Christian Beyer, Katrin Palumbo-Zerr, Yun Zhang, Stefan-Lutz Wollin, Jörg Distler. Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc). Eur Respir J 2015; 46: Suppl. 59, 3038
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
ILD-India registry: Idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD) associated interstitial lung disease (CTD-ILD)
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
The effects of tobramycin on pulmonary fibroblast function
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
IL-17+ cells immunoexpression in systemic sclerosis pulmonary fibrosis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy},
Source: Eur Respir J 2012; 40: 641-648
Year: 2012
Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Collagen V overexpression correlates with IL-17+ cells in C57BL/6 mice pulmonary remodeling
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Expression of hyaluronidase by interstitial myofibroblasts and epithelial cells is associated with fibrosis extension, clinical forms and pulmonary function stage in patients with systemic sclerosis
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010
Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF
Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models
Year: 2016
Detection of anti DFS70 antibodies in patients with interstitial lung disease (ILD) with and without connective tissue disease (CTD)
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Rituximab in severe, progressive interstitial lung disease
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Morphologic evaluation of lung in a scleroderma-like rabbit model
Source: Annual Congress 2006 - Systemic diseases, environmental and genetic factors in interstitial lung disease
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept